vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Service Properties Trust (SVC). Click either name above to swap in a different company.
Service Properties Trust is the larger business by last-quarter revenue ($296.5M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -0.3%, a 1.9% gap on every dollar of revenue. On growth, Pacira BioSciences, Inc. posted the faster year-over-year revenue change (5.0% vs -17.0%). Over the past eight quarters, Pacira BioSciences, Inc.'s revenue compounded faster (-0.2% CAGR vs -6.1%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...
PCRX vs SVC — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $296.5M |
| Net Profit | $2.9M | $-782.0K |
| Gross Margin | — | — |
| Operating Margin | 3.9% | -3.9% |
| Net Margin | 1.6% | -0.3% |
| Revenue YoY | 5.0% | -17.0% |
| Net Profit YoY | — | 99.0% |
| EPS (diluted) | $0.07 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $296.5M | ||
| Q3 25 | $179.5M | $377.6M | ||
| Q2 25 | $181.1M | $404.4M | ||
| Q1 25 | $168.9M | $335.0M | ||
| Q4 24 | $187.3M | $357.0M | ||
| Q3 24 | $168.6M | $390.9M | ||
| Q2 24 | $178.0M | $412.5M |
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-782.0K | ||
| Q3 25 | $5.4M | $-46.9M | ||
| Q2 25 | $-4.8M | $-38.2M | ||
| Q1 25 | $4.8M | $-116.4M | ||
| Q4 24 | — | $-76.4M | ||
| Q3 24 | $-143.5M | $-46.9M | ||
| Q2 24 | $18.9M | $-73.8M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -3.9% | ||
| Q3 25 | 3.5% | -12.8% | ||
| Q2 25 | 4.7% | -9.2% | ||
| Q1 25 | 1.2% | -33.3% | ||
| Q4 24 | 13.2% | -19.4% | ||
| Q3 24 | -82.8% | -12.8% | ||
| Q2 24 | 15.9% | -17.1% |
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -0.3% | ||
| Q3 25 | 3.0% | -12.4% | ||
| Q2 25 | -2.7% | -9.4% | ||
| Q1 25 | 2.8% | -34.8% | ||
| Q4 24 | — | -21.4% | ||
| Q3 24 | -85.1% | -12.0% | ||
| Q2 24 | 10.6% | -17.9% |
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $-0.01 | ||
| Q3 25 | $0.12 | $-0.28 | ||
| Q2 25 | $-0.11 | $-0.23 | ||
| Q1 25 | $0.10 | $-0.70 | ||
| Q4 24 | $0.38 | $-0.46 | ||
| Q3 24 | $-3.11 | $-0.28 | ||
| Q2 24 | $0.39 | $-0.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $346.8M |
| Total DebtLower is stronger | — | $5.5B |
| Stockholders' EquityBook value | $653.9M | $646.1M |
| Total Assets | $1.2B | $6.5B |
| Debt / EquityLower = less leverage | — | 8.52× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $346.8M | ||
| Q3 25 | $246.3M | $417.4M | ||
| Q2 25 | $445.9M | $63.2M | ||
| Q1 25 | $493.6M | $80.1M | ||
| Q4 24 | $484.6M | $143.5M | ||
| Q3 24 | $453.8M | $48.6M | ||
| Q2 24 | $404.2M | $14.6M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $5.5B | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $5.8B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $646.1M | ||
| Q3 25 | $727.2M | $647.9M | ||
| Q2 25 | $757.8M | $695.9M | ||
| Q1 25 | $798.5M | $734.6M | ||
| Q4 24 | $778.3M | $851.9M | ||
| Q3 24 | $749.6M | $929.0M | ||
| Q2 24 | $879.3M | $1.0B |
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $6.5B | ||
| Q3 25 | $1.3B | $7.0B | ||
| Q2 25 | $1.5B | $6.9B | ||
| Q1 25 | $1.6B | $7.0B | ||
| Q4 24 | $1.6B | $7.1B | ||
| Q3 24 | $1.5B | $7.1B | ||
| Q2 24 | $1.6B | $7.1B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | 8.52× | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 6.85× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-18.5M |
| Free Cash FlowOCF − Capex | — | $-95.2M |
| FCF MarginFCF / Revenue | — | -32.1% |
| Capex IntensityCapex / Revenue | — | 25.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-107.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-18.5M | ||
| Q3 25 | $60.8M | $98.1M | ||
| Q2 25 | $12.0M | $-7.0K | ||
| Q1 25 | $35.5M | $38.2M | ||
| Q4 24 | $33.1M | $-9.7M | ||
| Q3 24 | $53.9M | $106.2M | ||
| Q2 24 | $53.2M | $43.8M |
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-95.2M | ||
| Q3 25 | $57.0M | $57.9M | ||
| Q2 25 | $9.3M | $-46.6M | ||
| Q1 25 | $26.9M | $-23.2M | ||
| Q4 24 | $31.0M | $-88.9M | ||
| Q3 24 | $49.8M | $24.1M | ||
| Q2 24 | $51.6M | $-22.3M |
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -32.1% | ||
| Q3 25 | 31.7% | 15.3% | ||
| Q2 25 | 5.1% | -11.5% | ||
| Q1 25 | 15.9% | -6.9% | ||
| Q4 24 | 16.6% | -24.9% | ||
| Q3 24 | 29.6% | 6.2% | ||
| Q2 24 | 29.0% | -5.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 25.9% | ||
| Q3 25 | 2.2% | 10.6% | ||
| Q2 25 | 1.5% | 11.5% | ||
| Q1 25 | 5.1% | 18.3% | ||
| Q4 24 | 1.1% | 22.2% | ||
| Q3 24 | 2.4% | 21.0% | ||
| Q2 24 | 0.9% | 16.0% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
SVC
Segment breakdown not available.
